Europe Women’s Health Market Report

Europe Women’s Health Market Size

The Europe women’s health market size was calculated to be USD 14.68 billion in 2024 and is anticipated to be worth USD 22.30 billion by 2033, growing from USD 15.37 billion in 2025 at a CAGR of 4.76% during the forecast period.

Women’s health refers to the medical technologies, pharmaceuticals, digital health solutions, and specialized services designed to address physiological conditions unique to or disproportionately affecting women across their lifespan. This includes reproductive health, maternal care, menopause management, oncology, endocrinology, and mental well-being, with an increasing emphasis on personalized and preventive approaches. Unlike generalized healthcare segments, women’s health in Europe is defined by its integration of biological specificity, social equity, and policy-driven accessibility. Official reports from European agencies indicate ongoing analysis and efforts to understand and address gender-specific health needs and disparities in healthcare access and quality across the European Union. The European Union has significantly increased its investment in research and innovation projects focused on women's health through its Horizon Europe program, addressing conditions like endometriosis and polycystic ovary syndrome, and emphasizing the integration of a gender dimension in research by default. Furthermore, there is a growing awareness and policy drive within European Union institutions to address structural gender inequalities in medical research and healthcare access, which is expected to influence future national medical curricula and health policies. This convergence of clinical rigor, policy support, and patient advocacy positions the market as a cornerstone of Europe’s evolving commitment to gender responsive healthcare.

MARKET DRIVERS

Policy Mandates for Gender Equity in Clinical Research and Care Delivery

European regulatory and funding bodies are actively dismantling historical gender bias in medicine by mandating female inclusion in trials and funding condition-specific research, which in turn fuels the growth of the Europe women’s health market. Funding bodies within the European Union are increasingly encouraging and requiring the integration of sex and gender analysis into health research designs to enhance scientific quality and address historical biases in medical studies. The number of registered clinical trials focused on previously under-researched women's health conditions, such as endometriosis, has been steadily rising in recent years, reflecting increased research interest and data transparency efforts. France has expanded its national health insurance coverage for fertility preservation procedures, increasing access for a greater number of women with non-medical indications to support reproductive choices. Similarly, Germany’s Federal Joint Committee expanded coverage for menopause hormone therapy following longitudinal data on cardiovascular risk reduction. These policy shifts not only improve access but also validate women’s health as a distinct clinical discipline, driving demand for specialized diagnostics, therapeutics, and counseling services across public and private sectors.

Rising Health Literacy and DigitalSelf-Advocacyy Among Women

European women are increasingly informed, proactive, and digitally empowered in managing their health journeys, which further contributes to the expansion of the Europe women’s health market. There is a general observation of widespread utilization of validated health applications and online portals by a specific demographic cohort to monitor various health metrics, including physiological cycles, related physical manifestations, and consistency in taking prescribed medication. A notable trend in some northern European populations indicates that a significant majority of individuals engage with professionally assessed digital materials to conduct preliminary personal research prior to having a conversation about potential therapeutic avenues with medical professionals. This self-advocacy fuels demand for transparent evidence-based care and accelerates adoption of innovations like at-home fertility testing, tele gynecology, and AI-driven symptom checkers. As per sources, women are more likely than men to seek second opinions or switch providers based on online reviews. This informed consumerism pressures healthcare systems to elevate quality responsiveness and personalization, which transforms women from passive recipients into active participants who shape service design and clinical engagement across the women’s health landscape.

MARKET RESTRAINTS

Persistent Underfunding ofNon-Reproductivee Women’s Health Conditions

Funding remains disproportionately skewed toward maternal and reproductive care, despite policy advances, while conditions like endometriosis, menopause, and autoimmune disorders face chronic underinvestment. This is one of the major restraints to the Europe women’s health market. A notable trend indicates that a relatively small fraction of health research funding is allocated to health conditions in women that are not related to reproduction. Research funding dedicated to conditions impacting many individuals across Europe appears disproportionately low compared to the prevalence of these conditions. One specific condition, which affects several million women, receives a minimal share of research funding within the field of gynecology. A pattern of extended waiting periods has been observed for individuals to receive a diagnosis across several regions, suggesting systemic delays in care. This gap stifles innovation in diagnostics and therapeutics, limiting market expansion beyond fertility and contraception. Lack of equal funding is the root cause of the current disparity in women's healthcare, where reproductive services are prioritized. In contrast, other essential physiological needs throughout a woman's life are ignored.

Fragmented Access to Specialized Care Across Rural and Eastern Regions

Geographic disparities in specialist availability create significant barriers to timely and comprehensive women’s health services. Consequently, this hinders the expansion of the Europe women’s health market. There is a noticeable variance in the proximity to specialized medical services, such as gynecological care, for residents in different European regions. Certain rural municipalities exhibit significantly lower rates of timely access to these specific medical practitioners compared to those in urban areas of Western Europe. Geographic distance and associated travel expenses appear to be factors that influence the likelihood of individuals forgoing preventative health screenings in some areas. A shortfall in the number of certified specialists for particular health phases, such as menopause, has been identified in at least one nation to meet the existing need. Telehealth adoption remains limited by broadband gaps and regulatory restrictions on cross-border consultations. This inequity not only compromises health outcomes but constrains market potential in high-need regions where digital and mobile health solutions could bridge gaps, if supported by infrastructure and reimbursement policies aligned with urban standards.

MARKET OPPORTUNITIES

Integration of Menopause Care into Primary and Occupational Health Frameworks

Menopause is emerging as a high-impact opportunity as European institutions recognize its systemic effects on workforce participation and long term health, which is expected to drive the growth of the Europe women’s health market. A smaller number within this same demographic report considering an adjustment to their retirement timelines. In response to these trends, a health service in a specific country established a network of specialty support centers. Another jurisdiction implemented a regulation requiring certain employers to have support measures in place for menopause in the workplace. The European Commission’s Workforce Health Initiative now funds pilot programs in Germany and the Netherlands, integrating hormone therapy counseling into occupational health services. Additionally, digital platforms like MenoPal EU offer symptom tracking and clinician messaging. Shifting menopause from a private struggle to a managed health transition unlocks scalable pathways in employer-sponsored care, digital therapeutics, and preventive cardiology, moving it beyond niche clinics and into mainstream health systems.

Expansion of Fertility Preservation Beyond Oncology Indications

Fertility preservation is rapidly evolving from a cancer support service to a mainstream elective offering driven by social and biological awareness, which creates potential prospects for the Europe women’s health market. A considerable number of these procedures are linked to non-medical factors such as professional planning and personal relationship timing. Legislative changes in some countries have broadened public funding for elective fertility preservation, making it more accessible to a wider population beyond primary urban centers. National health systems in certain areas have integrated fertility cycles into standard coverage to promote reproductive autonomy for particular age ranges. Fertility preservation is progressively becoming part of corporate wellness plans offered by private companies. The inclusion of these services as a standard employment benefit aligns with an elevated rate of workforce participation. This normalization, supported by policy employer action and reduced stigma, creates a resilient and growing segment that bridges reproductive choice, preventive medicine, and long-term family planning.

MARKET CHALLENGES

Regulatory Ambiguity Around Digital Women’s Health Tools and Data Privacy

The rapid proliferation of femtech apps and remote monitoring devices faces inconsistent regulatory oversight across the region, which creates uncertainty for developers and clinicians, and thereby impedes the expansion of the Europe women’s health market. Regulatory classification for menstrual and fertility tracking applications remains inconsistent across various jurisdictions, particularly when these tools are utilized for diagnostic functions. Disparities in how these applications are categorized contribute to fluctuating standards for safety and efficacy within the digital health market. Data privacy assessments indicate that a significant number of popular women’s health platforms distribute sensitive user information to third parties without obtaining specific, granular consent. Regulatory bodies have moved to suspend certain cycle-prediction applications following concerns over the validity of their clinical claims. The intersection of health technology and data protection continues to face oversight challenges as authorities monitor the transparency of data-sharing practices. This patchwork discourages investment inhigh-qualityy digital therapeutics and erodes user trust. Innovation in AI-driven women’s health tools will continue to be fragmented and clinically unvalidated until the EU establishes harmonized guidelines under the Medical Devices Regulation.

Stigma and Cultural Taboos Limiting Open Dialogue and Early Intervention

Social and cultural barriers continue to suppress open discussion around menstruation, menopause, and sexual health in many European communities, which slows down the growth of the Europe women’s health market. A significant number of women in some Southern and Eastern European countries are hesitant to discuss gynecological symptoms with family or employers, often due to shame or fear of judgment. In one nation, a majority of adolescents report not receiving formal menstrual education before their first menstruation. This pattern of silence and lack of education may contribute to delays in seeking care for perimenopausal symptoms, with many individuals waiting a long time before consulting a healthcare professional. Such stigma also impedes public health campaigns and workplace accommodations, reducing market readiness for solutions that require user engagement. Overcoming these deep-rooted norms demands coordinated efforts in education, media representation, and community health outreach, without which even the most advanced interventions may fail to achieve meaningful adoption.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Application Insights

The contraceptives segment dominated the Europe women’s health market by accounting for a 58.5% share in 2024. The dominance of the contraceptives segment is driven by universal access policies and evolving delivery modalities. Contraceptives are deeply embedded in Europe’s public health infrastructure, with many EU member states providing partial or full reimbursement through national health systems. A significant majority of women in specific age demographics across some Western European nations have access to hormonal birth control without incurring direct costs at the point of service. The implementation of government support that covers all forms of contraception, including long-acting reversible options, aligns with policies aimed at ensuring equitable access to sexual and reproductive health services. Broad institutional support contributes to high and consistent usage of prescription contraception methods among the female population across the continent. Additionally, school-based sexual education programs in countries like Denmark and the Netherlands normalize early and informed contraceptive use, establishing lifelong adherence patterns that sustain market demand. Advancements in formulation and administration have significantly improved compliance and satisfaction. There is a notable increase in the selection of subdermal implants and hormonal intrauterine devices among individuals seeking reproductive healthcare. This trend suggests a growing preference for contraceptive options characterized by extended duration of use and reduced user intervention. Healthcare counseling frameworks have increasingly highlighted the reliability of long-acting methods compared to those requiring daily compliance. Clinical guidance patterns appear to be influencing a broader shift in patient choices toward reversible methods with high efficacy. Furthermore, digital adherence tools such as smart pill dispensers and cycle tracking integrations have reduced failure rates for oral contraceptives. These innovations address historical pain points like forgetfulness and side effects, transforming contraception from a routine obligation into a seamless component of women’s daily health management.

The menopause segment is predicted to witness the highest CAGR of 11.4% from 2025 to 2033. The growth of the menopause segment is propelled by workforce retention policies and clinical reclassification. Governments and employers are increasingly treating menopause as a legitimate health condition requiring accommodation and support. Several European nations have implemented formal workplace frameworks to support individuals experiencing menopausal symptoms. Certain regulatory measures now include provisions for environmental adjustments, such as temperature-controlled spaces, to improve employee comfort. Organizational policies are increasingly incorporating flexible scheduling and access to professional support services as standard accommodations. A significant number of major corporate entities across various sectors have voluntarily integrated menopause-specific protocols into their internal human resources strategies. There is a broader trend toward formalizing health-related workplace inclusivity, reflecting an evolving understanding of employee wellness needs. This shift drives demand for hormone therapy, non-hormonal alternatives, and digital symptom management tools. Reframing menopause as a public health issue rather than a private burden would establish formal support channels that transcend individual consumer demand. National health authorities are updating guidelines to reflect new evidence on the safety and benefits of menopausal hormone therapy. Prescribing protocols in one major European nation have been updated to favor specific bioidentical hormone therapy options for women under 60 experiencing common menopausal symptoms, which appears to be influencing a shift in prescriber behavior away from previous hesitation. In a different European nation, the reinstatement of full financial coverage for a specific form of hormone therapy, after a prolonged period of limited access, has correlated with a significant increase in the number of prescriptions issued within a short timeframe. Additionally, digital therapeutics like cognitive behavioral therapy apps for sleep and mood are now eligible for partial reimbursement in Sweden and the Netherlands under mental health parity laws. These regulatory evolutions dismantle historical barriers and position menopause care as a standard component of midlife health maintenance.

By Drug Class Insights

The hormonal therapies segment led the Europe women’s health market by capturing a 63.3% share in 2024. The leading position of the hormonal therapies segment is credited to physiological necessity and therapeutic breadth. Hormonal agents are fundamental to regulating menstrual cycles, enabling fertility control, and mitigating menopausal decline. Many women in Europe use hormonal formulations for a variety of clinical indications. These treatments are applied for issues like reproductive health management and bone density preservation. Some regional guidelines recommend hormonal therapy for individuals with early ovarian function loss. Such treatments aim to support long-term health stability, especially for the cardiovascular and skeletal systems. The incorporation of these therapies into standard practice shows a trend of managing endocrine-related health risks with pharmacological support. The clinical indispensability of these agents, supported by decades of outcome data, ensures consistent prescribing across primary and specialist care. Moreover, newer bioidentical and transdermal formulations have improved safety profiles, reducing thromboembolic risk compared to older oral estrogens, as per sources. This evolution sustains physician confidence and patient adherence. Hormonal therapies are increasingly positioned as preventive tools rather than symptomatic relief. According to the European Menopause and Andropause Society, initiating hormone therapy for symptomatic women in early menopause (before age 60 or within a decade of menopause onset) offers more favorable outcomes in terms of benefits versus potential risks. These findings have influenced national guidelines, with Switzerland and Finland now including hormone therapy in preventive health checklists for women over 50. Additionally, the European Commission’s Healthy Ageing Initiative funds longitudinal studies on hormonal modulation of immune senescence, reinforcing its role in systemic health. Given the aging demographic in Europe, this preventative approach extends the therapeutic window, thereby warranting sustained use and redefining hormonal therapies as continuous health investments rather than merely cyclical interventions.

The pain and symptom management segment is estimated to register the fastest CAGR of 12.7% during the forecast period due to condition-specific innovation and patient-centered care models. New non opioid agents are emerging for endometriosis, adenomyosis, and dysmenorrhea, conditions historically managed with inadequate analgesics. A pattern is emerging in addressing chronic, hormone-related conditions, shifting toward treatments that modify underlying disease processes rather than offering temporary symptom management. A recently approved therapy for pelvic pain has shown significant effectiveness and a favorable side effect profile compared to established treatments. Clinical adoption of this therapy has been rapid in some regions. A similar shift is occurring in the management of hormone-related menopausal symptoms, with a different class of medications showing promise in reducing symptom frequency and severity. These precision approaches address the root cause of pain, transforming management from palliative to therapeutic. Women increasingly demand holistic pain strategies that combine pharmaceuticals with digital and behavioral tools. A notable majority of women experiencing persistent gynecological pain are currently utilizing a multi-modal treatment approach that integrates pharmaceutical options, physical rehabilitation, and digital wellness tools. Structured treatment approaches for endometriosis across a specific region have broadened to encompass a standard combination of specialized physical therapy, cognitive strategies, and advanced nerve-focused treatments. The implementation of these integrated care pathways is associated with a decrease in dependency on strong pain relief medications within the described patient group. Furthermore, national health systems in Sweden and Germany reimburse digital therapeutics for menstrual pain, including biofeedback and virtual reality distraction. This convergence of pharmacological and non-pharmacological modalities reflects apatient-ledd shift toward personalized pain control that respects biological complexity and quality of life, which fuels rapid adoption and market expansion.

By Age Insights

The women aged 50 and above segment was the largest segment in the Europe women’s health market by holding a share of 41.6% in 2024. The supremacy of the women aged 50 and above segment is attributed to extended life expectancies and multi-condition management needs. Women across the region are experiencing longer lifespans following the onset of midlife, which broadens the timeframe available for proactive wellness strategies. This demographic is increasingly focused on the concurrent management of hormonal transitions, skeletal integrity, and various chronic health risks. A significant portion of pharmaceutical utilization for hormone regulation and bone density maintenance is attributed to this specific age group. The availability of comprehensive wellness coverage within national health frameworks correlates with high engagement in preventative gynecological screenings. Also, the integration of routine examinations and specialized treatments indicates a shift toward more comprehensive health monitoring for women in the latter half of their lives. The shift from acute to chronic care transforms this demographic into consistent high-value users of preventive and therapeutic services. Their health literacy and insurance coverage enable sustained engagement, driving volume and value across pharmaceuticals, diagnostics, and digital health. Contrary to outdated assumptions, a significant portion of European women remain professionally active past 50. According to sources, a portion of women aged 50 to 64 are employed across the EU, with hot flashes, sleep disruption, and fatigue directly impacting productivity. This reality has catalyzed demand for discreet, effective symptom control. The economic incentive to retain experienced female talent aligns with health needs, creating institutional demand for integrated solutions that support both well-being and workplace continuity.

The women aged 35 to 49 segment is anticipated to witness the fastest CAGR of 10.9% from 2025 to 2033, owing to fertility extension and preventive health awareness. European women are postponing childbirth. This trend drives demand for ovulation induction, fertility monitoring, and elective egg freezing. The establishment of public reimbursement frameworks has expanded access to elective oocyte cryopreservation, facilitating reproductive planning for a broader demographic. Fertility assessments have become integrated into standard corporate wellness offerings within specific European jurisdictions, reflecting an evolving approach to employee healthcare. There is a notable shift toward prioritizing reproductive health within both state-funded and private sector benefit structures. An upward trend in the utilization of specialized fertility services suggests a growing emphasis on proactive family planning measures. Organizational health strategies are increasingly incorporating comprehensive reproductive support to address evolving workforce needs. This proactive approach transforms reproductive health from crisis intervention to planned life stage management. Women in this bracket increasingly seek care for early perimenopausal symptoms, insulin resistance, and mood changes. Women in their forties are increasingly seeking medical advice for changes in menstrual cycles and sleep. In response, healthcare providers in some areas are offering comprehensive services to address these issues. Digital platforms focused on cycle tracking also show a large user base among women in this age group, suggesting proactive health management through personal data. This preventive orientation expands market participation beyond traditional reproductive services into integrated longevity care.

REGIONAL ANALYSIS

Germany Women’s Health Market Analysis

Germany outperformed other countries in the Europe women’s health market by accounting for a 19.5% share in 2024. The dominance of the German market is driven by universal coverage, robust primary care integration, and strong regulatory science. Statutory health insurers reimburse a comprehensive range of services including contraception, fertility treatment,s menopause management, and endometriosis care with minimal co-payments. The country has thousands of certified gynecologists. Additionally, Germany leads in clinical research with a portion of EU trials on non-hormonal menopause therapies conducted in its university hospitals. This blend of access to evidence and infrastructure creates a high-volume, high-quality market that sets clinical standards for the region.

France Women’s Health Market Analysis

France was the next prominent country in the Europe women’s health market by holding a share of 16.2% in 2024. The expansion of the French market is propelled by proactive public health policy, reproductive autonomy, and pharmaceutical innovation. France was the first EU country to fully reimburse elective egg freezing and offers free contraception to all women under 25. Furthermore, French pharmaceutical companies lead in developing next-generation hormonal therapies with a share of EU-approved bioidentical formulations originating from French R&D centers. This combination of social policy, scientific leadership, and universal access establishes France as a model for comprehensive women’s health delivery.

United Kingdom Women’s Health Market Analysis

The United Kingdom captured a significant share of the Europe women’s health market due to integrated national services, strong patient advocacy, and rapid policy adoption. Specialized healthcare provision is evident through the operation of numerous dedicated clinics focusing on menopause care across the nation. There is a nationwide approach to reproductive health, characterized by the provision of accessible long-acting reversible contraception. Workplace health initiatives are expanding, with a significant number of corporate entities adopting specific guidelines related to menopause support. A growing pattern in healthcare is the integration and broad utilization of digital health tools, particularly applications focused on managing conditions such as endometriosis and fertility tracking. Despite Brexit, the UK maintains alignment with EU clinical standards, ensuring continued innovation and cross-border research collaboration in women’s health.

Sweden Women’s Health Market Analysis

Sweden experienced a steady growth in the Europe women’s health market owing to gender equity integration, preventive care, and digital innovation. The country provides free contraception counseling and IUD insertion to all women under 25 and includes menopause support in universal occupational health programs. Sweden’s national electronic health record system enables seamless coordination between gynecologists, endocrinologists, and mental health providers, ensuring holistic care. Furthermore, a notable share of Swedish women use government-endorsed health apps for cycle and symptom tracking. This data-driven proactive model reduces diagnostic delays and positions Sweden as a leader in personalized women’s health at scale.

Italy Women’s Health Market Analysis

Italy is predicted to expand in the Europe women’s health market from 2025 to 2033 due to high specialist density, cultural emphasis on women’s well-being, and strong pharmaceutical manufacturing. Italy has thousands of gynecology clinics with a notable share offering integrated menopause and bone health services. The national health service fully covers hormonal therapy for women with premature ovarian insufficiency and provides free cervical and breast cancer screening with significant participation rates. Additionally, Italian research institutions lead in endometriosis biomarker discovery with diagnostic tests approved by the European Medicines Agency. This fusion of clinical access, scientific output, and cultural prioritization sustains Italy’s influential role in shaping Southern Europe’s women’s health landscape.

COMPETITION OVERVIEW

The Europe women’s health market features a dynamic mix of multinational pharmaceutical giants, specialized biotech firms, and digital health innovators competing on scientific credibility, clinical depth, and patient centricity. Unlike commoditized therapeutic areas, competition here is less about price and more about trust, evidence, and holistic support. Large players like Bayer leverage scale and legacy, while pure play companies such as Theramex and Organon differentiate through focused portfolios and rapid adaptation to emerging needs like endometriosis and perimenopausal care. Regulatory complexity across 27 member states creates both barriers and opportunities—favoring companies with strong local market access teams and adaptable compliance frameworks. Simultaneously, digital entrants are reshaping engagement by offering remote diagnostics and community support, though they often lack clinical validation. The market rewards those who combine rigorous science with empathetic design and proactive policy collaboration, ensuring that innovation translates into real-world impact for women across the life course.

KEY MARKET PLAYERS

A few major players of the Europe women’s health market include

• Bayer AG
• Roche Holding AG
• Merck KGaA
• Novartis AG
• Sanofi SA
• Pfizer Inc
• Abbott Laboratories
• Johnson & Johnson
• Gedeon Richter Plc
• Ferring Pharmaceuticals
• Organon & Co
• Ipsen Pharma
• Hologic Inc
• CooperSurgical
• Teva Pharmaceutical Industries Ltd

Top Strategies Used by the Key Market Participants

Key players in the Europe women’s health market pursue four core strategies to drive sustainable impact and differentiation. First, they align product portfolios with evolving clinical guidelines on menopause, endometriosis, and fertility to ensure therapeutic relevance and reimbursement eligibility. Second, they integrate digital health tools such as symptom trackers, telehealth interfaces, and adherence platforms to enhance patient engagement and longitudinal care. Third, they forge partnerships with national health systems, patient advocacy groups, and medical societies to co-develop education programs and improve early diagnosis. Fourth, they prioritize regulatory harmonization by securing centralized European Medicines Agency approvals and tailoring access pathways to national pricing and coverage frameworks. These strategies collectively enable companies to navigate Europe’s fragmented yet high-standard healthcare landscape while advancing both clinical outcomes and patient autonomy.

Leading Players in the Market

• Bayer AG is a global leader in women’s health with a deep legacy in hormonal therapeutics and reproductive care across Europe. The company’s portfolio includes widely used oral contraceptives, menopausal hormone therapies, and non-hormonal treatments for gynecological conditions. It also launched a pan-European educational initiative on endometriosis in partnership with patient advocacy groups to reduce diagnostic delays. These actions reinforce Bayer’s commitment to combining pharmaceutical innovation with patient empowerment and access, which strengthens its role as a trusted, science-driven partner in Europe’s evolving women’s health landscape.
• Organon & Co has established a focused presence in the Europe women’s health market through its dedicated portfolio spanning contraception, fertility, menopause, and osteoporosis. Originally spun off from Merck, the company prioritizes women-centric innovation and health equity. It also partnered with the European Menopause Society to train healthcare providers on updated hormone therapy guidelines. Additionally, Organon funded community screening programs for bone health in rural Poland and Greece. These initiatives reflect its mission to address both clinical and access gaps, positioning the company as a purpose-driven specialist committed to closing the women’s health equity divide in diverse European settings.
• Theramex is a pure play women’s health company headquartered in London with strong operational roots across France, Germany, and Spain. It specializes in branded generics and innovative therapies for contraception, menopause, and rare gynecological disorders. The company also enhanced its digital patient support platform, offering symptom diaries, teleconsultation links, and treatment reminders in many languages. Furthermore, Theramex collaborated with national health ministries to include its osteoporosis treatments in preventive care formularies for postmenopausal women. Theramex enhances its standing as a responsive, integrated partner in the personalized European women's health ecosystem by combining quick regulatory action, deep clinical expertise, and broad multilingual digital outreach.

MARKET SEGMENTATION

This research report on the Europe women’s health market has been segmented and sub-segmented based on application, drug class, age, and region.

By Application

• Contraceptives
• Menopause

By Drug Class

• Hormonal Therapies
• Pain and Symptom Management

By Age

• 50 Years
• Above

By Region

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe